{"filing":{"accession_number":"0001104659-26-091671","cik":"0001710072","ticker":"EWTX","company_name":"Edgewise Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tm2621653d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/tm2621653d1_8k.htm"},"events":[{"id":25411,"run_id":23064,"accession_number":"0001104659-26-091671","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Item 2.02 discloses Edgewise's second quarter 2026 financial results via press release, including R\u0026D expenses ($47.5M), G\u0026A expenses ($14.4M), and net loss ($57.3M or $0.53 per share). The filing explicitly states \"Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026,\" with the full press release attached as Exhibit 99.1. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational performance.","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26234,"accession_number":"0001104659-26-091671","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Edgewise's second quarter 2026 financial results via press release, including R\u0026D expenses ($47.5M), G\u0026A expenses ($14.4M), and net loss ($57.3M or $0.53 per share). The filing explicitly states \"Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026,\" with the full press release attached as Exhibit 99.1. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:45.133179+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26234,"accession_number":"0001104659-26-091671","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Edgewise's second quarter 2026 financial results via press release, including R\u0026D expenses ($47.5M), G\u0026A expenses ($14.4M), and net loss ($57.3M or $0.53 per share). The filing explicitly states \"Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026,\" with the full press release attached as Exhibit 99.1. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:45.133179+00:00","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-08-06"}]}